|
ATE557013T1
(de)
*
|
2004-03-16 |
2012-05-15 |
Boehringer Ingelheim Int |
Glucopyranosyl-substituierte benzol-derivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
|
|
CA2587639A1
(en)
|
2004-12-16 |
2006-06-22 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
|
ATE445608T1
(de)
|
2005-02-23 |
2009-10-15 |
Boehringer Ingelheim Int |
Glucopyranosylsubstituierte ((hetero)arylethynyl- benzyl)-benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose- cotransporters typ 2 (sglt2)
|
|
ATE453656T1
(de)
|
2005-04-15 |
2010-01-15 |
Boehringer Ingelheim Int |
Glucopyranosyl-substituierte (heteroaryloxy- benzyl)-benzen-derivate als sglt-inhibitoren
|
|
US7723309B2
(en)
|
2005-05-03 |
2010-05-25 |
Boehringer Ingelheim International Gmbh |
Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
|
|
UA91546C2
(uk)
|
2005-05-03 |
2010-08-10 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
|
|
US7772191B2
(en)
|
2005-05-10 |
2010-08-10 |
Boehringer Ingelheim International Gmbh |
Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
|
|
TW200726755A
(en)
*
|
2005-07-07 |
2007-07-16 |
Astellas Pharma Inc |
A crystalline choline salt of an azulene derivative
|
|
ES2346347T3
(es)
|
2005-07-27 |
2010-10-14 |
Boehringer Ingelheim International Gmbh |
Derivados de ((hetero)cicloalquiletinil-bencil)-benceno y su uso como inhibidores del cotransportador de glucosa dependiente de sodio (sglt).
|
|
CA2620566A1
(en)
|
2005-08-30 |
2007-03-08 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
|
TW200745075A
(en)
|
2005-09-08 |
2007-12-16 |
Boehringer Ingelheim Int |
Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments
|
|
AR056195A1
(es)
|
2005-09-15 |
2007-09-26 |
Boehringer Ingelheim Int |
Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
|
|
WO2007093610A1
(en)
|
2006-02-15 |
2007-08-23 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
|
|
PE20080697A1
(es)
|
2006-05-03 |
2008-08-05 |
Boehringer Ingelheim Int |
Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
|
|
JP5230613B2
(ja)
*
|
2006-05-23 |
2013-07-10 |
テラコス・インコーポレイテッド |
グルコース輸送体阻害剤およびその使用方法
|
|
CA2656847A1
(en)
|
2006-08-15 |
2008-02-21 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
|
|
CA2664095A1
(en)
*
|
2006-09-21 |
2008-03-27 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
|
TWI499414B
(zh)
|
2006-09-29 |
2015-09-11 |
Lexicon Pharmaceuticals Inc |
鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
|
|
US8283326B2
(en)
|
2006-10-27 |
2012-10-09 |
Boehringer Ingelheim International Gmbh |
Crystalline form of 4-(beta-D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
|
|
AR063569A1
(es)
*
|
2006-11-06 |
2009-02-04 |
Boehringer Ingelheim Int |
Derivados de benzil- benzonitrilo sustituidos con glucopiranosilo medicamentos que contienen a compuestos de este tipo su uso u procedimiento para su fabricacion
|
|
KR101100072B1
(ko)
*
|
2006-12-21 |
2011-12-29 |
고토부키 세이야쿠 가부시키가이샤 |
Ｃ-글리코시드 유도체의 제조방법 및 이의 합성 중간체
|
|
US7795228B2
(en)
*
|
2006-12-28 |
2010-09-14 |
Theracos, Inc. |
Spiroheterocyclic glycosides and methods of use
|
|
JP2010519273A
(ja)
*
|
2007-02-21 |
2010-06-03 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
四置換グルコピラノシル化ベンゼン誘導体、このような化合物を含む薬物、それらの使用及びそれらの製造方法
|
|
WO2008109591A1
(en)
*
|
2007-03-08 |
2008-09-12 |
Lexicon Pharmaceuticals, Inc. |
Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
|
|
PE20090938A1
(es)
|
2007-08-16 |
2009-08-08 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
|
|
MX2010002027A
(es)
|
2007-08-23 |
2010-03-15 |
Theracos Inc |
Derivados de bencilbenceno y metodos de uso.
|
|
MX2010002695A
(es)
*
|
2007-09-10 |
2010-04-01 |
Janssen Pharmaceutica Nv |
Proceso para la preparacion de compuestos utiles como inhibidores de transportador de glucosa dependiente de sodio (sglt).
|
|
JP5498392B2
(ja)
*
|
2007-11-30 |
2014-05-21 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
１，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｃｎｓ障害の治療のためのｐｄｅ９ａモジュレーターとしてのそれらの使用
|
|
UA101004C2
(en)
|
2007-12-13 |
2013-02-25 |
Теракос, Инк. |
Derivatives of benzylphenylcyclohexane and use thereof
|
|
ES2541141T3
(es)
*
|
2008-01-31 |
2015-07-16 |
Astellas Pharma Inc. |
Composición farmacéutica para el tratamiento de las enfermedades del hígado graso
|
|
UA105362C2
(en)
*
|
2008-04-02 |
2014-05-12 |
Бьорингер Ингельхайм Интернациональ Гмбх |
1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
|
|
US8791077B2
(en)
|
2008-05-22 |
2014-07-29 |
Astrazeneca Ab |
Method for treating hyperuricemia employing an SGLT2 inhibitor and composition containing same
|
|
AU2009270936B2
(en)
|
2008-07-15 |
2014-12-18 |
Theracos, Inc. |
Deuterated benzylbenzene derivatives and methods of use
|
|
MX2011001855A
(es)
|
2008-08-22 |
2011-03-24 |
Theracos Inc |
Procesos para la preparacion de inhibidores de sglt2.
|
|
MY155418A
(en)
*
|
2008-08-28 |
2015-10-15 |
Pfizer |
Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
|
|
JP5453431B2
(ja)
|
2008-09-08 |
2014-03-26 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ピラゾロピリミジン及びｃｎｓ障害の治療のためのそれらの使用
|
|
US9056850B2
(en)
|
2008-10-17 |
2015-06-16 |
Janssen Pharmaceutica N.V. |
Process for the preparation of compounds useful as inhibitors of SGLT
|
|
UY32427A
(es)
|
2009-02-13 |
2010-09-30 |
Boheringer Ingelheim Internat Gmbh |
Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
|
|
AP2011005795A0
(en)
|
2009-02-13 |
2011-08-31 |
Boehringer Ingelheim Int |
SGLT-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia.
|
|
BRPI1008560B1
(pt)
|
2009-02-13 |
2021-08-31 |
Boehringer Ingelheim International Gmbh |
Composição farmacêutica compreendendo um inibidor de sglt2, um inibidor de dpp-iv e opcionalmente um outro agente antidiabético e usos dos mesmos
|
|
KR101921934B1
(ko)
*
|
2009-02-13 |
2018-11-26 |
베링거 인겔하임 인터내셔날 게엠베하 |
글루코피라노실 디페닐메탄 유도체를 포함하는 약제학적 조성물, 이들의 약제학적 용량형, 이들의 제조방법 및 환자에서의 개선된 당 조절을 위한 이들의 용도
|
|
PE20120505A1
(es)
|
2009-03-31 |
2012-05-09 |
Boehringer Ingelheim Int |
Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona como moduladores de pde9a
|
|
US8541380B2
(en)
*
|
2009-06-19 |
2013-09-24 |
Green Cross Corporation |
C-aryl glucoside SGLT2 inhibitors and pharmaceutical compositions comprising same
|
|
US20110009347A1
(en)
*
|
2009-07-08 |
2011-01-13 |
Yin Liang |
Combination therapy for the treatment of diabetes
|
|
KR101532412B1
(ko)
|
2009-07-10 |
2015-06-29 |
얀센 파마슈티카 엔.브이. |
1-(β-Ｄ-글루코피라노실)-4-메틸-3-(5-(4-플루오로페닐)-2-티에닐메틸) 벤젠의 결정화 방법
|
|
AR077859A1
(es)
*
|
2009-08-12 |
2011-09-28 |
Boehringer Ingelheim Int |
Compuestos para el tratamiento de trastornos del snc
|
|
JP5758900B2
(ja)
|
2009-09-30 |
2015-08-05 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
グルコピラノシル置換ベンジルベンゼン誘導体の調製方法
|
|
AU2010303123B2
(en)
|
2009-09-30 |
2014-02-27 |
Boehringer Ingelheim International Gmbh |
Method for the preparation of a crystalline form of 1-chloro-4- (Beta-D-glucopyranos-1-yl)-2-(4-((S)-tetrahydrofuran-3-yloxy)benzyl)benzene
|
|
UY32919A
(es)
|
2009-10-02 |
2011-04-29 |
Boehringer Ingelheim Int |
Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
|
|
SI2488515T1
(sl)
|
2009-10-14 |
2017-04-26 |
Janssen Pharmaceutica Nv |
Postopek za pripravo spojin, ki so uporabne kot inhibitorji SGLT2
|
|
EA021983B1
(ru)
|
2009-11-02 |
2015-10-30 |
Пфайзер Инк. |
Производные диоксабицикло[3.2.1]октан-2,3,4-триола
|
|
WO2011070592A2
(en)
|
2009-12-09 |
2011-06-16 |
Panacea Biotec Ltd. |
Novel sugar derivatives
|
|
EP2552442A1
(en)
|
2010-03-30 |
2013-02-06 |
Boehringer Ingelheim International GmbH |
Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
|
|
TWI599360B
(zh)
|
2010-05-11 |
2017-09-21 |
健生藥品公司 |
醫藥調配物
|
|
WO2011153712A1
(en)
|
2010-06-12 |
2011-12-15 |
Theracos, Inc. |
Crystalline form of benzylbenzene sglt2 inhibitor
|
|
AP2012006631A0
(en)
|
2010-08-12 |
2012-12-31 |
Boehringer Ingelheim Int |
6-Cycloalkyl-1, 5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivatives and their use as PDE9A inhibitors
|
|
WO2012041898A1
(en)
|
2010-09-29 |
2012-04-05 |
Celon Pharma Sp. Z O.O. |
Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
|
|
US20120283169A1
(en)
|
2010-11-08 |
2012-11-08 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
US20130035281A1
(en)
|
2011-02-09 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
US8809345B2
(en)
|
2011-02-15 |
2014-08-19 |
Boehringer Ingelheim International Gmbh |
6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
|
|
CN102643256B
(zh)
*
|
2011-02-18 |
2014-12-24 |
上海璎黎科技有限公司 |
一种芳基糖苷类化合物及其制备方法和应用
|
|
AR085689A1
(es)
|
2011-03-07 |
2013-10-23 |
Boehringer Ingelheim Int |
Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
|
|
RS55056B1
(sr)
|
2011-04-13 |
2016-12-30 |
Janssen Pharmaceutica Nv |
Proces za pripremu jedinjenja koja su korisna kao inhibitori sglt2
|
|
KR101609859B1
(ko)
*
|
2011-04-25 |
2016-04-07 |
베이징 프릴루드 팜. 에스씨아이. & 테크. 씨오., 엘티디. |
소듐-의존적 포도당 운반 단백질의 억제제 및 이의 제조방법 및 용도
|
|
TWI542596B
(zh)
|
2011-05-09 |
2016-07-21 |
健生藥品公司 |
（２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
|
|
BR112013031032A2
(pt)
|
2011-06-03 |
2016-11-29 |
Boehringer Ingelheim Int |
inibidores de sglt-2 para o tratamento de distúrbios metabólicos em pacientes tratados com agentes neurolépticos
|
|
US20130035298A1
(en)
|
2011-07-08 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
US9018249B2
(en)
|
2011-09-13 |
2015-04-28 |
Panacea Biotec Limited |
SGLT inhibitors
|
|
CA2861066C
(en)
|
2012-01-12 |
2024-01-02 |
Yale University |
Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase
|
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
|
US9192617B2
(en)
|
2012-03-20 |
2015-11-24 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
US9193751B2
(en)
|
2012-04-10 |
2015-11-24 |
Theracos, Inc. |
Process for the preparation of benzylbenzene SGLT2 inhibitors
|
|
DK2981269T3
(da)
|
2013-04-04 |
2023-10-23 |
Boehringer Ingelheim Vetmedica Gmbh |
Behandling af stofskifteforstyrrelser hos hestedyr
|
|
US20140303097A1
(en)
|
2013-04-05 |
2014-10-09 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
CA2812519A1
(en)
|
2013-04-05 |
2014-10-05 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
HRP20190101T1
(hr)
|
2013-04-05 |
2019-03-08 |
Boehringer Ingelheim International Gmbh |
Terapeutske uporabe empagliflozina
|
|
US11813275B2
(en)
|
2013-04-05 |
2023-11-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
FI4000608T3
(fi)
|
2013-04-18 |
2026-01-21 |
Boehringer Ingelheim Int |
Farmaseuttinen koostumus, menetelmä hoitamiseksi ja sen käyttöjä
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
WO2015043511A1
(en)
|
2013-09-27 |
2015-04-02 |
Sunshine Lake Pharma Co., Ltd. |
Glucopyranosyl derivatives and their uses in medicine
|
|
WO2015051484A1
(en)
|
2013-10-12 |
2015-04-16 |
Theracos, Inc. |
Preparation of hydroxy-benzylbenzene derivatives
|
|
MX376097B
(es)
|
2013-12-17 |
2025-03-07 |
Boehringer Ingelheim Vetmedica Gmbh |
Inhibidores de sglt2 para usarse en el tratamiento o prevención de trastornos metabólicos en animales felinos.
|
|
US9902751B2
(en)
|
2013-12-30 |
2018-02-27 |
Mylan Laboratories Limited |
Process for the preparation of empagliflozin
|
|
CA2932674C
(en)
|
2014-01-23 |
2023-01-24 |
Boehringer Ingelheim Vetmedica Gmbh |
Treatment of metabolic disorders in canine animals
|
|
FI3721882T3
(fi)
|
2014-04-01 |
2024-09-24 |
Boehringer Ingelheim Vetmedica Gmbh |
Aineenvaihduntahäiriöiden hoito hevoseläimissä
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
MX388516B
(es)
|
2014-06-24 |
2025-03-20 |
Univ Kansas |
Bifenil amidas con grupos éter modificados como inhibidores de hsp90 e inductores de hsp70.
|
|
US10071164B2
(en)
|
2014-08-11 |
2018-09-11 |
Yale University |
Estrogen-related receptor alpha based protac compounds and associated methods of use
|
|
EP4403230A3
(en)
|
2014-09-25 |
2025-01-08 |
Boehringer Ingelheim Vetmedica GmbH |
Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
|
|
EA201791982A1
(ru)
|
2015-03-09 |
2020-02-17 |
Интекрин Терапьютикс, Инк. |
Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
|
|
AU2016310535B2
(en)
|
2015-08-27 |
2021-08-19 |
Boehringer Ingelheim Vetmedica Gmbh |
Liquid pharmaceutical compositions comprising SGLT-2 inhibitors
|
|
US20170071970A1
(en)
|
2015-09-15 |
2017-03-16 |
Janssen Pharmaceutica Nv |
Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
|
|
JP2018530592A
(ja)
|
2015-10-15 |
2018-10-18 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
代謝性ミオパチーの治療に使用するためのｓｇｌｔ−２阻害剤
|
|
AU2016349781A1
(en)
|
2015-11-02 |
2018-05-10 |
Yale University |
Proteolysis targeting chimera compounds and methods of preparing and using same
|
|
WO2017141202A1
(en)
|
2016-02-17 |
2017-08-24 |
Lupin Limited |
Complex of sglt2 inhibitor and process for preparation thereof
|
|
KR20250097990A
(ko)
|
2016-11-10 |
2025-06-30 |
베링거 인겔하임 인터내셔날 게엠베하 |
약제학적 조성물, 치료 방법 및 이의 용도
|
|
AU2018249822A1
(en)
|
2017-04-03 |
2019-10-31 |
Coherus Biosciences Inc. |
PPArgamma agonist for treatment of progressive supranuclear palsy
|
|
JP7508375B2
(ja)
|
2018-05-14 |
2024-07-01 |
リアタ ファーマシューティカルズ インコーポレイテッド |
熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド
|
|
KR102204439B1
(ko)
|
2018-05-14 |
2021-01-18 |
에이치케이이노엔 주식회사 |
Sglt-2 억제제 및 dpp-iv 억제제를 포함하는 약제학적 조성물
|
|
WO2020039394A1
(en)
|
2018-08-24 |
2020-02-27 |
Novartis Ag |
New drug combinations
|
|
KR102951944B1
(ko)
*
|
2019-07-05 |
2026-04-10 |
산동 단홍 파머수티컬 컴퍼니., 리미티드. |
SGLTs 억제제의 결정형 및 그 응용
|
|
CN114585358B
(zh)
*
|
2019-07-26 |
2023-11-10 |
东宝紫星(杭州)生物医药有限公司 |
一种SGLTs/DPP4抑制剂及其应用
|
|
EP4064854A1
(en)
|
2019-11-28 |
2022-10-05 |
Boehringer Ingelheim Vetmedica GmbH |
Use of sglt-2 inhibitors in the drying-off of non-human mammals
|
|
JP7423800B2
(ja)
|
2020-02-17 |
2024-01-29 |
ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー |
ネコにおける心臓疾患の予防および／または治療のためのｓｇｌｔ－２阻害剤の使用
|
|
CA3173808A1
(en)
|
2020-03-06 |
2021-09-10 |
Vertex Pharmaceuticals Incorporated |
Methods of treating apol-1 dependent focal segmental glomerulosclerosis
|
|
WO2022051316A1
(en)
|
2020-09-03 |
2022-03-10 |
Coherus Biosciences, Inc. |
Fixed dose combinations of chs-131 and a sglt-2 inhibitor
|
|
CN117715639A
(zh)
|
2021-07-28 |
2024-03-15 |
勃林格殷格翰动物保健有限公司 |
Sglt-2抑制剂用于预防和/或治疗非人哺乳动物中的肾脏病的用途
|
|
MX2024001184A
(es)
|
2021-07-28 |
2024-02-27 |
Boehringer Ingelheim Vetmedica Gmbh |
Uso de inhibidores de sglt-2 para la prevencion y/o tratamiento de cardiopatias en mamiferos no humanos, que excluye felinos, en particular, caninos.
|
|
WO2023227492A1
(en)
|
2022-05-25 |
2023-11-30 |
Boehringer Ingelheim Vetmedica Gmbh |
Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
|
|
JP2026508912A
(ja)
|
2023-03-06 |
2026-03-13 |
ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー |
液体医薬組成物、特に１種又は複数のｓｇｌｔ－２阻害剤を含む液体医薬組成物の送達のためのシステム
|
|
CN121175053A
(zh)
|
2023-05-24 |
2025-12-19 |
勃林格殷格翰动物保健有限公司 |
包含一或多种sglt-2抑制剂及替米沙坦的非人类哺乳动物中肾脏疾病和/或高血压的组合治疗和/或预防
|
|
TW202508593A
(zh)
|
2023-05-24 |
2025-03-01 |
德商百靈佳殷格翰維美迪加股份有限公司 |
包含一或多種sglt-2抑制劑及匹莫苯坦(pimobendan)及/或替米沙坦(telmisartan)之非人類哺乳動物心臟病之組合治療及/或預防
|